[Skip to Content]
[Skip to Content Landing]
Views 637
Citations 0
Research Letter
January 2018

Pediatric Use of Antipsychotic Medications Before and After Medicaid Peer Review Implementation

Author Affiliations
  • 1Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore
  • 2Department of Psychiatry, University of Maryland, Baltimore
  • 3Now with Merck & Co Inc
  • 4Acumen, LLC, Burlingame, California
  • 5Centers for Medicare & Medicaid Services, Washington, DC
JAMA Psychiatry. 2018;75(1):100-103. doi:10.1001/jamapsychiatry.2017.3493

In response to the growing cardiometabolic safety concerns about the use of atypical antipsychotic (AAP) medications in children,1,2 several state Medicaid agencies have adopted a novel, more clinically nuanced and individualized approach to reviewing the appropriateness of AAP use, namely, peer review prior authorization (PA) policies.3 Physicians must receive preapproval through contracted clinicians (peer reviewers) to prescribe AAPs to certain-aged children. We assessed the effect of peer review PA policies on AAP use among Medicaid-insured youth according to age restriction criteria.